



## **Protalix BioTherapeutics to Present at the 2015 J.P. Morgan Healthcare Conference**

January 5, 2015

CARMIEL, Israel, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that Moshe Manor, the Company's President and Chief Executive Officer, will present a corporate overview at the 33<sup>rd</sup> Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 11:30 AM PT. The conference will be held at the Westin St. Francis Union Square Hotel in San Francisco on January 12-15, 2015. A live webcast of the presentation will be available at [www.protalix.com](http://www.protalix.com) on the event calendar page. A replay will be archived and available after the conclusion of the presentation for 90 days.

### **About Protalix BioTherapeutics, Inc.**

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx<sup>®</sup>. Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012, by Israel's Ministry of Health in September 2012, by the Brazilian National Health Surveillance Agency (ANVISA) in March 2013, by the Mexican Federal Commission for the Protection against Sanitary Risk (COFEPRIS) in April 2013, by the Australian Therapeutic Goods Administration (TGA) in May 2014 and by the regulatory authorities of other countries. Marketing applications for taliglucerase alfa have been filed in additional territories as well. Protalix has partnered with Pfizer Inc. for the worldwide development and commercialization of taliglucerase alfa, excluding Israel and Brazil, where Protalix retains full rights. Protalix's development pipeline includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-112, an orally-delivered glucocerebrosidase enzyme that is produced and encapsulated within carrot cells, also for the treatment of Gaucher disease; PRX-106, an orally-delivered treatment for the treatment of Inflammatory Bowel Disease; PRX-110 for the treatment of Cystic Fibrosis; and others.

CONTACT: Investor Contact  
Marcy Nanus  
The Trout Group, LLC  
646-378-2927  
[mnanus@troutgroup.com](mailto:mnanus@troutgroup.com)

Protalix BioTherapeutics, Inc.